Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse

Clinical and Experimental Immunology

Volumn 180, Issue 3, 2015, Pages 432-441

  Ramaglia, V ^a   Jackson, S J ^b   Hughes, T R ^a   Neal, J W ^a   Baker, D ^b   Morgan, B P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chronic relapsing; Complement; Experimental autoimmune encephalomyelitis (EAE); Multiple sclerosis

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; COMPLEMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BIOZZI MOUSE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IN SITU HYBRIDIZATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; ANIMAL; DISEASE MODEL; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, BIOZZI; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84929509654     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12595     Document Type: Article

References (44)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502-17.
2. Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol 2014; 122:343-69.
3. Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46:296-304.
4. Filippi M, Rovaris M, Rice GP et al. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci 2000; 176:42-4.
5. Filippi M, Rocca MA, Pagani E et al. European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol 2004; 61:1409-12.
6. Molyneux PD, Kappos L, Polman C et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000; 123:2256-63.
7. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5:343-54.
8. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-97.
9. Hajishengallis G, Lambris JD. Complement and dysbiosis in periodontal disease. Immunobiology 2012; 217:1111-6.
10. Wang Q, Rozelle AL, Lepus CM et al. Identification of a central role for complement in osteoarthritis. Nat Med 2011; 17:1674-9.
11. Zhang X, Kohl J. A complex role for complement in allergic asthma. Expert Rev Clin Immunol 2010; 6:269-77.
12. Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308:385-9.
13. Edwards AO, Ritter R, III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308:421-4.
14. Sta M, Sylva-Steenland RM, Casula M et al. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis 2011; 42:211-20.
15. Lambert JC, Heath S, Even G et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:1094-9.
16. Howell GR, Macalinao DG, Sousa GL et al. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest 2011;121:1429-44.
17. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998;43:465-71.
18. Prineas JW, Kwon EE, Cho ES et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001; 50:646-57.
19. Barnett MH, Parratt JD, Cho ES, Prineas JW. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009; 65:32-46.
20. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-17.
21. Brink BP, Veerhuis R, Breij EC van der V, Dijkstra CD, Bo L. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 2005; 64:147-55.
22. Ingram G, Loveless S, Howell OW et al. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol Commun 2014; 2:53.
23. Schwab C, McGeer PL. Complement activated C4d immunoreactive oligodendrocytes delineate small cortical plaques in multiple sclerosis. Exp Neurol 2002; 174:81-8.
24. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002; 168:458-65.
25. Mead RJ, Neal JW, Griffiths MR et al. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Lab Invest 2004; 84:21-8.
26. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994; 152:5477-84.
27. Szalai AJ, Hu X, Adams JE, Barnum SR. Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Mol Immunol 2007; 44:3132-6.
28. Baker D, O'Neill JK, Gschmeissner SE, Wilcox CE, Butter C, Turk JL. Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J Neuroimmunol 1990; 28:261-70.
29. Hampton DW, Anderson J, Pryce G et al. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol 2008; 201-202:200-11. [CrossRef]
30. Bhole D, Stahl GL. Molecular basis for complement component 6 (C6) deficiency in rats and mice. Immunobiology 2004; 209:559-68.
31. Wetsel RA, Fleischer DT, Haviland DL. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. J Biol Chem 1990; 265:2435-40.
32. Ruseva MM, Hughes TR, Donev RM et al. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Mol Immunol 2009; 46:803-11.
33. Al-Izki S, Pryce G, O'Neill J K, Butter C, Giovannoni G, Amor S, Baker D. Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Mult Scler Rel Dis 2012; 1: 29-38.
34. Morgan BP. Measurement of complement hemolytic activity, generation of complement-depleted sera, and production of hemolytic intermediates. Methods Mol Biol 2000; 150:61-71.
35. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24:2040-8.
36. O'Neill JK, Baker D, Turk JL. Inhibition of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. J Neuroimmunol 1992; 41:177-87.
37. Pryce G, O'Neill JK, Croxford JL et al. Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J Neuroimmunol 2005; 165:41-52.
38. Donev RM, Morgan BP. A quantitative method for comparison of expression of alternatively spliced genes using different primer pairs. J Biochem Biophys Methods 2006; 66:23-31. [CrossRef]
39. Hampton DW, Serio A, Pryce G, et al. Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathol Commun 2013; 1:84. [CrossRef]
40. Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000; 6:88-91.
41. Ingram G, Hakobyan S, Robertson NP, Morgan BP. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol 2009; 155:128-39.
42. Jackson SJ, Lee J, Nikodemova M, Fabry Z, Duncan ID. Quantification of myelin and axon pathology during relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. J Neuropathol Exp Neurol 2009; 68:616-25. [CrossRef]
43. Whitham RH, Nilaver G, Bourdette DN, Seil FJ. Serum anti-myelin antibodies in chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol 1988; 18:155-70.
44. Morris MM, Piddlesden S, Groome N, Amor S. Anti-myelin antibodies modulate experimental allergic encephalomyelitis in Biozzi ABH mice.Biochem Soc Trans 1997; 25:168S.